Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

Presented by: Bayer
Sponsored by: Dendreon and Janssen Oncology
In-Kind Sponsor: Los Padres

Guest Speakers:

• Dr. Edwin Morales – Urology Specialist, San Antonio
• Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
• Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
• Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health

View the full video by clicking on the image below; or scroll down to access links to short video segments about specific content presented at the event.

Click any link listed below to go straight to that segment of the video:

• 0:01 – Introduction – Terri Likowski, Us TOO Program Director – Support Group Services
• 0:50 – Johnny Staha – Support Group Leader – San Antonio, TX
• 1:07 – Chuck Strand – CEO, Us TOO International
• 3:04 – Intro to Dr. Juan A. Reyna
• 4:44 – Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
• 10:00 – Intro to Dr. Edwin Morales
• 10:56 – Dr. Edwin Morales – Urology Specialist, San Antonio
• 11:01 – Prostate Cancer Overview, Definitions, Terms
• 11:52 – Biochemical Recurrence
• 14:29 – (Non) Metastatic Castrate Resistant Prostate Cancer
• 17:52 – The Androgen Receptor Axis
• 20:47 – Androgen Deprivation Therapy
• 21:17 – After ADT
• 23:00 – Options for Rising PSA After CAB/AAW
• 23:44 – Asymptomatic Non – Metastatic Castrate Resistant Prostate Cancer
• 26:36 – Options for Asymptomatic Non – Metastatic Castrate Resistant Prostate Cancer
• 32:16 – The "New" Natural History of Prostate Cancer
• 33:45 – Intro to Dr. Vijay Gunuganti
• 34:26 – Dr. Vijay Gunuganti – Oncologist at Texas Oncology
• 35:03 – Lifetime Probability of Developing Cancer
• 36:07 – Multidisciplinary Team Approach to PCa Management
• 37:02 – Treatment for CRPC
• 37:24 – Early Metastatic Prostate Cancer or Hormone Sensitive Prostate Cancer
• 37:58 – The CHAARTED Hypotheses
• 38:45 – LATITUDE Trial
• 39:19 – STAMPEDE Trial
• 39:33 – Results of Androgen Removal
• 40:17 – Castrate Resistant Metastatic Prostate Cancer or Hormone Refractory Prostate Cancer
• 40:59 – Enzalutamide
• 41:47 – Abiraterone
• 42:28 – Metastatic Bone Lesions
• 43:39 – Xofigo
• 44:10 – Phase III ALSYMPCA Study Design: Patient Eligibility
• 45:38 – Treatment of Symptomatic, Hormone Refractory Metastatic Disease with Chemotherapy
• 46:52 – Side Effects of Chemotherapy
• 48:07 – Currently Approved Therapy for Advanced Prostate Cancer
• 49:48 – Intro to Dr. Michael Liss
• 50:52 – Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
• 51:56 – Screening, PSA Testing, At – Risk Groups
• 54:35 – African American Men, Family History
• 55:18 – Individualized Risk Assessment Approach, Shared Decision Making
• 57:20 – Hereditary Prostate Cancer
• 58:43 – BRCA
• 58:54 – Genetics – Risk Using SNPs
• 59:50 – Functional vs. Non – Functional Genes
• 1:00:31 – Prostate Genetic Score
• 1:01:04 – Genomics for Treatment Decisions
• 1:04:56 – Future of Clinical Trials
• 1:06:11 – Prostate Imaging – MRI
• 1:08:29 – Software Detection Technologies, Restricted Spectrum Imaging
• 1:09:08 – PET/CT Imaging
• 1:10:32 – Oligometastatic Prostate Cancer Clinical Trials
• 1:12:35 – Q&A